Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 2.65
VRTX's Cash-to-Debt is ranked lower than
69% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. VRTX: 2.65 )
Ranked among companies with meaningful Cash-to-Debt only.
VRTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.66  Med: 2.47 Max: N/A
Current: 2.65
Equity-to-Asset 0.51
VRTX's Equity-to-Asset is ranked lower than
78% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. VRTX: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
VRTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.02  Med: 0.51 Max: 0.95
Current: 0.51
-0.02
0.95
Interest Coverage 3.81
VRTX's Interest Coverage is ranked lower than
100% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VRTX: 3.81 )
Ranked among companies with meaningful Interest Coverage only.
VRTX' s Interest Coverage Range Over the Past 10 Years
Min: 0.12  Med: 2.81 Max: 2.96
Current: 3.81
0.12
2.96
Piotroski F-Score: 8
Altman Z-Score: 11.53
Beneish M-Score: -2.71
WACC vs ROIC
14.34%
36.66%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 14.62
VRTX's Operating Margin % is ranked higher than
71% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. VRTX: 14.62 )
Ranked among companies with meaningful Operating Margin % only.
VRTX' s Operating Margin % Range Over the Past 10 Years
Min: -602.63  Med: -84.82 Max: 8.07
Current: 14.62
-602.63
8.07
Net Margin % 8.78
VRTX's Net Margin % is ranked higher than
68% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. VRTX: 8.78 )
Ranked among companies with meaningful Net Margin % only.
VRTX' s Net Margin % Range Over the Past 10 Years
Min: -630.27  Med: -90.57 Max: 2.1
Current: 8.78
-630.27
2.1
ROE % 15.75
VRTX's ROE % is ranked higher than
67% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. VRTX: 15.75 )
Ranked among companies with meaningful ROE % only.
VRTX' s ROE % Range Over the Past 10 Years
Min: -180.27  Med: -57.99 Max: 4.58
Current: 15.75
-180.27
4.58
ROA % 6.57
VRTX's ROA % is ranked higher than
72% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. VRTX: 6.57 )
Ranked among companies with meaningful ROA % only.
VRTX' s ROA % Range Over the Past 10 Years
Min: -58.14  Med: -27.38 Max: 1.51
Current: 6.57
-58.14
1.51
ROC (Joel Greenblatt) % 42.46
VRTX's ROC (Joel Greenblatt) % is ranked higher than
77% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. VRTX: 42.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VRTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1092.55  Med: -102.98 Max: 110.77
Current: 42.46
-1092.55
110.77
3-Year Revenue Growth Rate 8.90
VRTX's 3-Year Revenue Growth Rate is ranked higher than
57% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. VRTX: 8.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
VRTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -32.5  Med: 10.95 Max: 129.4
Current: 8.9
-32.5
129.4
3-Year EPS without NRI Growth Rate -41.00
VRTX's 3-Year EPS without NRI Growth Rate is ranked lower than
86% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. VRTX: -41.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
VRTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -41  Med: 10.3 Max: 94.9
Current: -41
-41
94.9
GuruFocus has detected 4 Warning Signs with Vertex Pharmaceuticals Inc $VRTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VRTX's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

VRTX Guru Trades in Q2 2016

George Soros 6,300 sh (New)
Manning & Napier Advisors, Inc 126,990 sh (New)
Joel Greenblatt 108,656 sh (+2053.31%)
Pioneer Investments 1,111,794 sh (+26.81%)
David Carlson 270,000 sh (+17.39%)
Vanguard Health Care Fund 12,914,741 sh (+1.95%)
Eaton Vance Worldwide Health Sciences Fund 528,100 sh (+225.99%)
John Paulson Sold Out
Steven Cohen Sold Out
Leucadia National Sold Out
Ken Fisher 5,112 sh (-0.83%)
Jim Simons 60,517 sh (-46.26%)
» More
Q3 2016

VRTX Guru Trades in Q3 2016

John Burbank 2,830 sh (New)
Jeremy Grantham 50,300 sh (New)
Manning & Napier Advisors, Inc 142,540 sh (+12.25%)
Pioneer Investments 1,231,092 sh (+10.73%)
Ken Fisher 5,168 sh (+1.10%)
Jeremy Grantham 100,000 sh (unchged)
Vanguard Health Care Fund 12,914,741 sh (unchged)
David Carlson 270,000 sh (unchged)
George Soros Sold Out
Jim Simons Sold Out
Joel Greenblatt 66,716 sh (-38.60%)
Eaton Vance Worldwide Health Sciences Fund 269,807 sh (-48.91%)
» More
Q4 2016

VRTX Guru Trades in Q4 2016

Steven Cohen 887,000 sh (New)
Paul Tudor Jones 9,611 sh (New)
Manning & Napier Advisors, Inc 2,126,020 sh (+1391.53%)
Jeremy Grantham 100,000 sh (+98.81%)
Vanguard Health Care Fund 13,230,341 sh (+2.44%)
Jeremy Grantham 100,000 sh (unchged)
David Carlson 270,000 sh (unchged)
Ken Fisher 5,168 sh (unchged)
John Burbank Sold Out
Joel Greenblatt Sold Out
Pioneer Investments 1,226,158 sh (-0.40%)
Eaton Vance Worldwide Health Sciences Fund 226,707 sh (-15.97%)
» More
Q1 2017

VRTX Guru Trades in Q1 2017

George Soros 3,600 sh (New)
Jim Simons 40,117 sh (New)
Pioneer Investments 1,518,822 sh (+23.87%)
Ken Fisher 5,213 sh (+0.87%)
David Carlson 270,000 sh (unchged)
Jeremy Grantham Sold Out
Paul Tudor Jones Sold Out
Vanguard Health Care Fund 13,014,973 sh (-1.63%)
Manning & Napier Advisors, Inc 1,764,419 sh (-17.01%)
Steven Cohen 271,663 sh (-69.37%)
Eaton Vance Worldwide Health Sciences Fund 180,739 sh (-20.28%)
» More
» Details

Insider Trades

Latest Guru Trades with VRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:ALIOY, NAS:INCY, NAS:ALXN, OTCPK:GIKLY, NAS:BMRN, OTCPK:CSLLY, OTCPK:NVZMF, OTCPK:UCBJY, OTCPK:GMXAY, NAS:REGN, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:TSRO, NAS:BIIB, NAS:BIVV, NAS:IONS, NAS:ALNY, NAS:EXEL, NAS:UTHR » details
Traded in other countries:VRTX.Austria, VX1.Germany, VRTX.Mexico, VRTX.Switzerland, 0QZU.UK,
Headquarter Location:USA
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. The firm's key drugs are Kalydeco and Orkambi for cystic fibrosis and has also several mid- and late-stage products targeting this market. Vertex successfully developed and commercialized two HIV protease inhibitors, which were outlicensed to GlaxoSmithKline. Vertex's pipeline includes therapies for the treatment of cancer, pain, inflammatory diseases, and influenza.

Ratios

vs
industry
vs
history
PE Ratio 171.31
VRTX's PE Ratio is ranked lower than
99.99% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. VRTX: 171.31 )
Ranked among companies with meaningful PE Ratio only.
VRTX' s PE Ratio Range Over the Past 10 Years
Min: 25.82  Med: 80.49 Max: 560.57
Current: 171.31
25.82
560.57
Forward PE Ratio 72.46
VRTX's Forward PE Ratio is ranked lower than
89% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. VRTX: 72.46 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 171.31
VRTX's PE Ratio without NRI is ranked lower than
99.99% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. VRTX: 171.31 )
Ranked among companies with meaningful PE Ratio without NRI only.
VRTX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 25.82  Med: 95.54 Max: 560.57
Current: 171.31
25.82
560.57
Price-to-Owner-Earnings 167.49
VRTX's Price-to-Owner-Earnings is ranked lower than
99.99% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. VRTX: 167.49 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
VRTX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 21.57  Med: 53.5 Max: 415.71
Current: 167.49
21.57
415.71
PB Ratio 19.90
VRTX's PB Ratio is ranked lower than
94% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. VRTX: 19.90 )
Ranked among companies with meaningful PB Ratio only.
VRTX' s PB Ratio Range Over the Past 10 Years
Min: 5.78  Med: 13.82 Max: 37.6
Current: 19.9
5.78
37.6
PS Ratio 14.63
VRTX's PS Ratio is ranked lower than
57% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. VRTX: 14.63 )
Ranked among companies with meaningful PS Ratio only.
VRTX' s PS Ratio Range Over the Past 10 Years
Min: 4.47  Med: 19.54 Max: 79.6
Current: 14.63
4.47
79.6
Price-to-Free-Cash-Flow 64.27
VRTX's Price-to-Free-Cash-Flow is ranked lower than
93% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. VRTX: 64.27 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
VRTX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.88  Med: 62.9 Max: 1635
Current: 64.27
12.88
1635
Price-to-Operating-Cash-Flow 57.30
VRTX's Price-to-Operating-Cash-Flow is ranked lower than
90% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. VRTX: 57.30 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
VRTX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.94  Med: 56.52 Max: 242.49
Current: 57.3
11.94
242.49
EV-to-EBIT 98.76
VRTX's EV-to-EBIT is ranked lower than
98% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. VRTX: 98.76 )
Ranked among companies with meaningful EV-to-EBIT only.
VRTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -277.8  Med: -12.2 Max: 2133.1
Current: 98.76
-277.8
2133.1
EV-to-EBITDA 82.12
VRTX's EV-to-EBITDA is ranked lower than
96% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. VRTX: 82.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
VRTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1067.2  Med: -13.1 Max: 297.1
Current: 82.12
-1067.2
297.1
Current Ratio 3.82
VRTX's Current Ratio is ranked lower than
69% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. VRTX: 3.82 )
Ranked among companies with meaningful Current Ratio only.
VRTX' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 4.6 Max: 30.95
Current: 3.82
1.14
30.95
Quick Ratio 3.65
VRTX's Quick Ratio is ranked lower than
67% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. VRTX: 3.65 )
Ranked among companies with meaningful Quick Ratio only.
VRTX' s Quick Ratio Range Over the Past 10 Years
Min: 1.14  Med: 4.6 Max: 30.95
Current: 3.65
1.14
30.95
Days Inventory 127.51
VRTX's Days Inventory is ranked higher than
54% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. VRTX: 127.51 )
Ranked among companies with meaningful Days Inventory only.
VRTX' s Days Inventory Range Over the Past 10 Years
Min: 62.49  Med: 122.98 Max: 254.87
Current: 127.51
62.49
254.87
Days Sales Outstanding 37.60
VRTX's Days Sales Outstanding is ranked higher than
67% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. VRTX: 37.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.75  Med: 45.26 Max: 61.46
Current: 37.6
25.75
61.46
Days Payable 111.45
VRTX's Days Payable is ranked higher than
68% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. VRTX: 111.45 )
Ranked among companies with meaningful Days Payable only.
VRTX' s Days Payable Range Over the Past 10 Years
Min: 106.57  Med: 382.26 Max: 1204.41
Current: 111.45
106.57
1204.41

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
VRTX's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. VRTX: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VRTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.2  Med: -12.35 Max: -2
Current: -2
-23.2
-2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3997.33
VRTX's Price-to-Net-Cash is ranked lower than
99.99% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. VRTX: 3997.33 )
Ranked among companies with meaningful Price-to-Net-Cash only.
VRTX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.55  Med: 18.85 Max: 3645
Current: 3997.33
3.55
3645
Price-to-Net-Current-Asset-Value 70.13
VRTX's Price-to-Net-Current-Asset-Value is ranked lower than
99% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. VRTX: 70.13 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VRTX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.16  Med: 7.11 Max: 1835.5
Current: 70.13
2.16
1835.5
Price-to-Tangible-Book 25.61
VRTX's Price-to-Tangible-Book is ranked lower than
95% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. VRTX: 25.61 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VRTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.88  Med: 8.08 Max: 120.7
Current: 25.61
1.88
120.7
Price-to-Intrinsic-Value-Projected-FCF 48.17
VRTX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. VRTX: 48.17 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
VRTX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 43.92  Med: 73.16 Max: 819.67
Current: 48.17
43.92
819.67
Price-to-Median-PS-Value 0.75
VRTX's Price-to-Median-PS-Value is ranked higher than
64% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. VRTX: 0.75 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VRTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 1 Max: 3.83
Current: 0.75
0.26
3.83
Price-to-Graham-Number 13.96
VRTX's Price-to-Graham-Number is ranked lower than
99.99% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. VRTX: 13.96 )
Ranked among companies with meaningful Price-to-Graham-Number only.
VRTX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.35  Med: 9.52 Max: 40.01
Current: 13.96
2.35
40.01
Earnings Yield (Greenblatt) % 1.01
VRTX's Earnings Yield (Greenblatt) % is ranked higher than
69% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. VRTX: 1.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VRTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 1.6 Max: 5.4
Current: 1.01
0.1
5.4

More Statistics

Revenue (TTM) (Mil) $2,019
EPS (TTM) $ 0.70
Beta2.03
Short Percentage of Float1.86%
52-Week Range $71.46 - 121.96
Shares Outstanding (Mil)249.07

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,115 2,682 3,391
EPS ($) 1.50 3.31 5.36
EPS without NRI ($) 1.50 3.31 5.36
EPS Growth Rate
(Future 3Y To 5Y Estimate)
75.46%
Dividends per Share ($)
» More Articles for VRTX

Headlines

Articles On GuruFocus.com
Eaton Vance Worldwide Health Sciences Fund 1st Quarter Investment Report May 02 2017 
Galapagos NV Tests Cystic Fibrosis Treatment on First Patient Feb 03 2017 
Galapagos NV Announces Results From Cystic Fibrosis Treatment Study Dec 27 2016 
Piotroski F-Score in the Real World Dec 19 2016 
Testing of Treatment for Cystic Fibrosis Patients Begins Nov 29 2016 
Edward Owens Top 2nd Quarter Investments Aug 03 2016 
Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 

More From Other Websites
Vertex CEO: Our goal is to have one medicine for all cyst... May 23 2017
Vertex Undergoes FTC Scrubbing for Deal on CF Treatment May 22 2017
Amgen, Gilead, Biogen Won't Lead The Biotech Boom — So Who Will? May 19 2017
Vertex launches college scholarship program for cystic fibrosis patients, families May 19 2017
Vertex Awards 40 Scholarships Totaling $200,000 to People Living with Cystic Fibrosis and Their... May 19 2017
Vertex to Present at the UBS Healthcare Conference on May 23 May 18 2017
Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion May 18 2017
Zacks.com featured highlights: Covanta Holding, PTC, Etsy, Vertex Pharmaceuticals and Live Nation... May 18 2017
Vertex Pharmaceuticals' Shares Pop in Afterhours Trading After FDA Approval while AstraZeneca Sinks... May 18 2017
Vertex boosts Kalydeco sales forecast after FDA approves for more patients May 18 2017
Vertex shares up more than 1% after FDA drug approval May 17 2017
FDA Approves KALYDECO® (ivacaftor) for More Than 900 People Ages 2 and Older with Cystic Fibrosis... May 17 2017
Love High-Growth? Here Are 3 Stocks to Consider May 17 2017
5 Toxic Stocks to Steer Clear Of or Play Short Right Now May 17 2017
Why Is Vertex Pharma (VRTX) Stock Soaring This Year? May 16 2017
Henri Termeer, 'giant of biotech' and longtime CEO of Genzyme, dies at 71 May 14 2017
3 Best Stocks in Personalized Medicine May 14 2017
CWALT, Inc. Mortgage Pass-Through Certificates, Series 2006-45T1 -- Moody's Affirms Seven Classes of... May 11 2017
I Still Can't Believe Gilead Sciences, Inc. Spent $14.8 Billion on Shareholder Rewards May 09 2017
Here's Why Vertex Pharmaceuticals Incorporated Gained 8% in April May 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)